Alphamab Oncology of Suzhou closed a $60 million Series B led by Hudson Bay Capital Management to support its biologic oncology drug business. Using its experience in protein development, Alphamab is building a portfolio of multi-functional biologic therapies for cancer indications, including bispecific and mix-mAb platforms. The company will use the money for R&D and manufacturing facilities, clinical development of its pipeline and upcoming commercial launch of its lead candidate. In November 2018, Alphamab raised $130 million in a Series A financing. More details....
Share this with colleagues: